BR112017003905A2 - composições da matriz extracelular - Google Patents
composições da matriz extracelularInfo
- Publication number
- BR112017003905A2 BR112017003905A2 BR112017003905A BR112017003905A BR112017003905A2 BR 112017003905 A2 BR112017003905 A2 BR 112017003905A2 BR 112017003905 A BR112017003905 A BR 112017003905A BR 112017003905 A BR112017003905 A BR 112017003905A BR 112017003905 A2 BR112017003905 A2 BR 112017003905A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- extracellular matrix
- ecm
- elisa
- measured
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title abstract 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title abstract 5
- 210000002744 extracellular matrix Anatomy 0.000 title abstract 5
- 102000016359 Fibronectins Human genes 0.000 abstract 2
- 108010067306 Fibronectins Proteins 0.000 abstract 2
- 230000003169 placental effect Effects 0.000 abstract 2
- 210000005059 placental tissue Anatomy 0.000 abstract 2
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 102000016942 Elastin Human genes 0.000 abstract 1
- 108010014258 Elastin Proteins 0.000 abstract 1
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 229920002549 elastin Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
são proporcionadas aqui composições de matriz extracelular placentária (ecm) e métodos de produzir as mesmas. são também aqui proporcionadas as utilizações das composições ecm placentárias aqui proporcionadas. em um aspecto, aqui proporcionado são composições de matriz extracelular (ecm) preparadas utilizando tecido de placenta, por exemplo, tecido de placenta humana. em certas concretizações, as composições ecm aqui proporcionadas compreendem cerca de 30% a cerca de 60% de colágeno e cerca de 10% a cerca de 35% de elastina. além disso, tais composições ecm compreendem (i) quantidades muito baixas de fibronectina (por exemplo, menos de 0,1% de fibronectina), p.e., tal como medido por elisa; (ii) nenhum ou uma quantidade indetectável de laminina, p. e, como medida por elisa; e / ou nenhum ou uma quantidade indetectável de glicosaminoglicanos, p.e., tal como medido por elisa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462041468P | 2014-08-25 | 2014-08-25 | |
| PCT/US2015/046690 WO2016033041A1 (en) | 2014-08-25 | 2015-08-25 | Extracellular matrix compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017003905A2 true BR112017003905A2 (pt) | 2018-03-06 |
Family
ID=55400430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017003905A BR112017003905A2 (pt) | 2014-08-25 | 2015-08-25 | composições da matriz extracelular |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20170056479A1 (pt) |
| EP (1) | EP3185888B1 (pt) |
| JP (3) | JP2017525732A (pt) |
| KR (2) | KR20170040809A (pt) |
| CN (1) | CN106794227B (pt) |
| AU (2) | AU2015306811A1 (pt) |
| BR (1) | BR112017003905A2 (pt) |
| CA (1) | CA2958211C (pt) |
| EA (1) | EA201790461A1 (pt) |
| IL (1) | IL250753A0 (pt) |
| MX (1) | MX2017002469A (pt) |
| MY (1) | MY193650A (pt) |
| NZ (1) | NZ729021A (pt) |
| SG (2) | SG11201701114UA (pt) |
| WO (1) | WO2016033041A1 (pt) |
| ZA (1) | ZA201701059B (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015080901A1 (en) | 2013-11-26 | 2015-06-04 | Celleration Inc. | Systems and methods for producing and delivering ultrasonic therapies for wound treatment and healing |
| JP6712160B2 (ja) * | 2016-03-29 | 2020-06-17 | 株式会社Adeka | エンドトキシン測定のための前処理方法及びその測定方法 |
| US11318168B2 (en) | 2016-06-24 | 2022-05-03 | Osiris Therapeutics, Inc. | Human tissue derived compositions and uses thereof |
| EP3490673A4 (en) * | 2016-07-29 | 2020-07-22 | Alliqua Biomedical, Inc. | SYSTEMS AND METHODS FOR DELIVERING CELLULAR AND BIOLOGICAL MATERIALS USING ULTRASONICS FOR THE TREATMENT AND HEALING OF WOUNDS |
| CN107349463A (zh) * | 2017-06-16 | 2017-11-17 | 卓阮医疗科技（苏州）有限公司 | 一种生物源性止血微粒及其制备方法 |
| US11026980B1 (en) * | 2018-02-26 | 2021-06-08 | Triad Life Sciences, Inc. | Flowable birth tissue composition and related methods |
| CN109125799A (zh) * | 2018-09-05 | 2019-01-04 | 张强 | GelMA水凝胶人脱细胞羊膜三维双层辅料的制备方法 |
| CN110841115A (zh) * | 2019-11-13 | 2020-02-28 | 中国科学院遗传与发育生物学研究所 | 一种胶原凝胶支架及其在提高自体脂肪细胞移植存活率中的应用 |
| CN116600833A (zh) * | 2020-05-26 | 2023-08-15 | 康维德公司 | 修饰猪支架及其制备方法 |
| JP7189468B2 (ja) | 2021-01-08 | 2022-12-14 | ダイキン工業株式会社 | 不具合箇所推定システム、不具合箇所推定方法、及びプログラム |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615373B2 (en) * | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
| CN1478547A (zh) * | 2002-08-28 | 2004-03-03 | 赵晓红 | 胶原蛋白保健胶囊 |
| AU2005322068B2 (en) * | 2004-12-23 | 2011-09-01 | Ethicon Incorporated | Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells |
| CA2602029C (en) * | 2005-03-11 | 2014-07-15 | Wake Forest University Health Sciences | Tissue engineered blood vessels |
| AT502395B1 (de) * | 2005-07-27 | 2007-03-15 | Iep Gmbh | Oxidoreduktasen zur stereoselektiven reduktion von ketoverbindungen |
| CN1739797A (zh) * | 2005-09-06 | 2006-03-01 | 易康富生物科技(南通)有限公司 | 一种补充胶原蛋白的复合配方 |
| US9694034B2 (en) * | 2005-10-31 | 2017-07-04 | Bio Solution Co., Ltd. | Artificial cartilage containing chondrocytes obtained from costal cartilage and preparation process thereof |
| JP5769925B2 (ja) * | 2006-10-06 | 2015-08-26 | アントフロゲネシス コーポレーション | ヒト胎盤コラーゲン組成物、並びにそれらの製造方法及び使用方法 |
| US20080279833A1 (en) * | 2007-05-10 | 2008-11-13 | Matheny Robert G | Laminate sheet articles for tissue regeneration |
| US20090023885A1 (en) * | 2007-07-16 | 2009-01-22 | Texas State University - San Marcos | Treatment method for imparting high impact resistance in certain cbdo copolymers |
| CA2694700C (en) * | 2007-07-27 | 2015-04-14 | Humacyte, Inc. | Compositions and methods for soft tissue augmentation |
| WO2010053918A1 (en) * | 2008-11-05 | 2010-05-14 | Hancock Jaffe Laboratories, Inc. | Composite containing collagen and elastin as a dermal expander and tissue filler |
| WO2010135527A2 (en) * | 2009-05-20 | 2010-11-25 | Humacyte, Inc. | Elastin for soft tissue augmentation |
| US8652500B2 (en) * | 2009-07-22 | 2014-02-18 | Acell, Inc. | Particulate tissue graft with components of differing density and methods of making and using the same |
| ES2768968T3 (es) * | 2009-08-25 | 2020-06-24 | Tissue Tech Inc | Productos de la membrana amniótica del cordón umbilical |
| US9908691B2 (en) * | 2010-06-30 | 2018-03-06 | Gpcp Ip Holdings Llc | Dispenser and sheet product dispensing plate therefor |
| US8722854B2 (en) * | 2010-12-23 | 2014-05-13 | Medskin Solutions Dr. Suwelack Ag | Degradation-stabilised, biocompatible collagen matrices |
| US20120189586A1 (en) * | 2011-01-21 | 2012-07-26 | Carl Randall Harrell | Human Placental Derived Extracellular Matrix and Uses Therof |
| AU2013312924A1 (en) * | 2012-09-04 | 2015-03-19 | Anthrogenesis Corporation | Methods of tissue generation |
| JP2016501245A (ja) * | 2012-12-07 | 2016-01-18 | アントフロゲネシス コーポレーション | 胎盤細胞外マトリクスを使用する口腔病変の治療 |
| US20150037436A1 (en) * | 2013-07-30 | 2015-02-05 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
| MX2016010293A (es) * | 2014-02-11 | 2017-02-23 | Anthrogenesis Corp | Micro-organoides, y metodos de fabricacion y usos los mismos. |
-
2015
- 2015-08-25 CA CA2958211A patent/CA2958211C/en active Active
- 2015-08-25 SG SG11201701114UA patent/SG11201701114UA/en unknown
- 2015-08-25 BR BR112017003905A patent/BR112017003905A2/pt active Search and Examination
- 2015-08-25 CN CN201580054755.2A patent/CN106794227B/zh active Active
- 2015-08-25 MX MX2017002469A patent/MX2017002469A/es unknown
- 2015-08-25 EA EA201790461A patent/EA201790461A1/ru unknown
- 2015-08-25 EP EP15836120.4A patent/EP3185888B1/en active Active
- 2015-08-25 JP JP2017511949A patent/JP2017525732A/ja active Pending
- 2015-08-25 WO PCT/US2015/046690 patent/WO2016033041A1/en active Application Filing
- 2015-08-25 KR KR1020177008216A patent/KR20170040809A/ko active Application Filing
- 2015-08-25 KR KR1020237029541A patent/KR20230129618A/ko not_active Application Discontinuation
- 2015-08-25 AU AU2015306811A patent/AU2015306811A1/en not_active Abandoned
- 2015-08-25 NZ NZ729021A patent/NZ729021A/en unknown
- 2015-08-25 MY MYPI2017700469A patent/MY193650A/en unknown
- 2015-08-25 SG SG10201901713RA patent/SG10201901713RA/en unknown
-
2016
- 2016-11-01 US US15/340,924 patent/US20170056479A1/en not_active Abandoned
-
2017
- 2017-02-13 ZA ZA2017/01059A patent/ZA201701059B/en unknown
- 2017-02-23 IL IL250753A patent/IL250753A0/en unknown
-
2020
- 2020-05-27 JP JP2020092044A patent/JP2020142114A/ja active Pending
-
2021
- 2021-04-12 AU AU2021202201A patent/AU2021202201A1/en active Pending
-
2022
- 2022-06-13 JP JP2022094947A patent/JP2022130466A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170040809A (ko) | 2017-04-13 |
| IL250753A0 (en) | 2017-04-30 |
| CA2958211C (en) | 2023-09-26 |
| CN106794227B (zh) | 2022-03-01 |
| EA201790461A1 (ru) | 2017-07-31 |
| WO2016033041A1 (en) | 2016-03-03 |
| JP2017525732A (ja) | 2017-09-07 |
| MX2017002469A (es) | 2017-05-19 |
| CN106794227A (zh) | 2017-05-31 |
| NZ729021A (en) | 2022-12-23 |
| JP2022130466A (ja) | 2022-09-06 |
| SG11201701114UA (en) | 2017-03-30 |
| AU2021202201A1 (en) | 2021-05-06 |
| MY193650A (en) | 2022-10-21 |
| ZA201701059B (en) | 2018-04-25 |
| EP3185888B1 (en) | 2023-06-07 |
| SG10201901713RA (en) | 2019-03-28 |
| CA2958211A1 (en) | 2016-03-03 |
| US20170056479A1 (en) | 2017-03-02 |
| EP3185888A4 (en) | 2018-06-20 |
| KR20230129618A (ko) | 2023-09-08 |
| EP3185888A1 (en) | 2017-07-05 |
| AU2015306811A1 (en) | 2017-03-09 |
| JP2020142114A (ja) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017003905A2 (pt) | composições da matriz extracelular | |
| CO2017011851A2 (es) | Compuestos novedosos | |
| BR112018004536A2 (pt) | peptídeos de endereçamento à cartilagem | |
| BR112015017174A2 (pt) | preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico | |
| MX2017012206A (es) | Proliferacion ex vivo de celulas epiteliales. | |
| BR112015011933A2 (pt) | composições bacterianas sinérgicas e métodos de produção e uso das mesmas | |
| BR112015010283A8 (pt) | bactéria gram-negativa modificada para a produção de um polissacarídeo, glicoproteína recombinante, métodos de produzir uma glicoproteína recombinante e de produzir uma vacina de gliconjugado, célula de e. coli modificada, e, vacina | |
| BR112017019412A2 (pt) | proteínas ligadoras de tslp | |
| WO2015048344A3 (en) | Silk/platelet composition and use thereof | |
| IN2015DN00017A (pt) | ||
| BR112017005997A2 (pt) | método | |
| MX2016004556A (es) | Composicion de hueso comprimido y metodo para usar la misma. | |
| BR112016016539A2 (pt) | micro-organismos recombinantes enriquecidos com carboidratos | |
| BR112016022055A2 (pt) | elementos de ligação ao tnf alfa | |
| BR112017001550A2 (pt) | enxerto de tecido | |
| MX2017014245A (es) | Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas. | |
| PH12017501070A1 (en) | Peptides and their use in the treatment of skin | |
| BR112013006938A2 (pt) | kits, componentes e métodos para reconstrução de tecido | |
| NZ703345A (en) | Compositions and methods for reducing frequency and/or severity of headache | |
| PE20131065A1 (es) | Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular | |
| EP4275746A3 (en) | Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use | |
| PH12014502627B1 (en) | Anti-ageing composition containing dehydrogenated abietic acid as active ingredient | |
| BR112015004178A2 (pt) | gluconato de clorexidina solubilizado em um monoacilglicerídeo hidrofóbico | |
| WO2015076717A3 (en) | Mscs in the treatment of cardiac disorders | |
| GB201110777D0 (en) | Methods and uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |